David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

Consultant Physician

Genetics and Genomics

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.

Key publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Recent publications

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.
Journal article

Bergsland CH. et al, (2020), ESMO Open, 5
Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars.
Journal article

Jazieh AR. et al, (2020), JCO Glob Oncol, 6, 1461 - 1471
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
Journal article

Lee LYW. et al, (2020), Lancet Oncol
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Journal article

Lee LY. et al, (2020), Lancet, 395, 1919 - 1926
The burgeoning role of global health diplomacy to alleviate suffering of cancer patients in low- and middle-income countries.
Journal article

Adomako M. et al, (2020), Int Health, 12, 231 - 233

More publications